search
Back to results

Efficacy of an Oral Rehydration Solution Containing the Probiotic Lactobacillus Reuteri Protectis and Zinc in Infants With Acute Gastroenteritis

Primary Purpose

Acute Gastroenteritis

Status
Completed
Phase
Not Applicable
Locations
Greece
Study Type
Interventional
Intervention
ORS rehydration solution
placebo
Sponsored by
Alexandra Papadopoulou
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Gastroenteritis focused on measuring Acute gastroenteritis, Probiotics, Lactobacillus reuteri, Zinc supplementation, Infants, Age 6 months to 36 months

Eligibility Criteria

6 Months - 36 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 6 - 36 months old children
  • 3 or more watery or soft stools per day for the past 24-48 hours
  • Clinically judged as having mild to moderate dehydration (Bailey scale scores 1 to 4)
  • Available throughout the study period
  • Re-examination on the 7th day from the enrolment
  • The signed informed consent by one/both parents or legal guardian
  • Parents or legal guardian should have the mental ability to understand and willingness to fulfil all the details of the protocol

Exclusion Criteria:

  • Diarrhoea lasting more than 48 h
  • Clinical signs of severe dehydration (Bailey scale scores = or > 5)
  • Malnutrition as judged by a body weight/height ratio below the 5th percentile
  • Clinical signs of a coexisting severe acute systemic illness (meningitis, sepsis, pneumonia)
  • Immunodeficiency
  • Severe chronic disease including cystic fibrosis
  • Food allergy diagnosed by physician or other chronic gastrointestinal diseases
  • Use of pre-/probiotics in the previous 2 weeks, for example infant formula containing probiotics and/or prebiotics.
  • Use of antibiotics or any anti-diarrhoeal medication in the previous 4 weeks

Sites / Locations

  • Athens Children's Hospital "AGIA SOPHIA"

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

ORS with probiotic and zinc

Placebo Comparator

Arm Description

ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate

Standard oral rehydration solution

Outcomes

Primary Outcome Measures

Resolution of diarrhoea.
Proportion of children without watery (3A ISS by Amsterdam infant stool scale ) or soft (3B ISS Amsterdam infant stool scale) stools on day 2 of treatment. Day 0 = day of enrolment and start of treatment, day 1 = first complete day of treatment Time from start of treatment and until last watery or soft stool.

Secondary Outcome Measures

Reduction of severity of diarrhoea
Reduction of severity of diarrhoea will be evaluated as though : Number of watery (type 3A ISS ) and soft ( 3B ISS) stools daily on each of the day of the therapy and up to 5 days. Proportion of children with watery (3A ISS) and soft ( 3B ISS) stools on each of the day 1-5 (Day 0 = day of enrolment and start of treatment, day 1 = first complete day of treatment) Νumber of vomiting episodes: per child on each of the treatment days 1-5. Volume of ORS intake during the first 24h of treatment. Need of hospitalization Absence of workdays for the parents. Child's absence from day care / nursery. Medication needed for treatment of diarrhoea.

Full Information

First Posted
June 22, 2013
Last Updated
February 20, 2016
Sponsor
Alexandra Papadopoulou
Collaborators
BioGaia AB
search

1. Study Identification

Unique Protocol Identification Number
NCT01886755
Brief Title
Efficacy of an Oral Rehydration Solution Containing the Probiotic Lactobacillus Reuteri Protectis and Zinc in Infants With Acute Gastroenteritis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
July 2013 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Alexandra Papadopoulou
Collaborators
BioGaia AB

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An ORS with L. reuteri DSM 17938 and zinc is expected to reduce duration and severity of symptoms in infants and young children with acute gastroenteritis.
Detailed Description
Oral rehydration solution is recommended for treatment and prevention of dehydration due to acute gastroenteritis in infants and children (WHO/UNICEF, 2004; ESPGHAN / ESPID Guidelines, 2008). Acute diarrhoea may lead to zinc depletion in infants, and zinc supplementation is recommended in infants and children with acute gastroenteritis living in developing countries. In developed countries however, the studies on the efficacy of zinc supplementation in children with acute gastroenteritis are few and conflicting. Selected strains of probiotics, including L. reuteri ATCC 55730, have been shown in several studies to reduce the duration and the severity of diarrhoea in children with acute gastroenteritis and the effect is greater if the probiotics are given within 60 hours from the onset of symptoms. Lactobacillus reuteri (L. reuteri) has been shown to reduce the duration and severity of acute gastroenteritis in children aged 6-36 months. In these studies L. reuteri was reported to have clinical effect on diarrhoea of both bacterial and viral (rotavirus) origin. Furthermore, L. reuteri strain DSM 17938 has recently been shown to reduce the duration of watery diarrhoea by 1.2 days among 6-36 mo old Italian children with acute gastroenteritis treated in hospital. The present study is a prospective, randomized, double blind, controlled study with parallel groups. The planned investigation is designed to compare the efficacy of an ORS with L. reuteri DSM 17938 and zinc to an ORS with similar osmolarity and content of salts but without L. reuteri DSM 17938 and zinc, on the duration and severity of acute gastroenteritis. 92 children aged 6-36 months seen at private pediatric clinics and/or at the emergency clinics of the Athens Childrens Hospital "AGIA SOPHIA", and treated either as outpatients or as inpatients will be recruited until the final sample size is reached. Assuming a difference of 30% between groups in the primary outcome of prevalence of diarrhoea on day 2, and estimating an attrition rate of approximately 15%, the final sample size will be 92 subjects, or 46 subjects in each arm. Data collection points will be on day 7 at the outpatient clinic of the Division of Pediatric Gastroenterology & Nutrition of the First Department of Paediatrics, Athens University Hospital.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Gastroenteritis
Keywords
Acute gastroenteritis, Probiotics, Lactobacillus reuteri, Zinc supplementation, Infants, Age 6 months to 36 months

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
51 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ORS with probiotic and zinc
Arm Type
Experimental
Arm Description
ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
Arm Title
Placebo Comparator
Arm Type
Placebo Comparator
Arm Description
Standard oral rehydration solution
Intervention Type
Dietary Supplement
Intervention Name(s)
ORS rehydration solution
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo
Primary Outcome Measure Information:
Title
Resolution of diarrhoea.
Description
Proportion of children without watery (3A ISS by Amsterdam infant stool scale ) or soft (3B ISS Amsterdam infant stool scale) stools on day 2 of treatment. Day 0 = day of enrolment and start of treatment, day 1 = first complete day of treatment Time from start of treatment and until last watery or soft stool.
Time Frame
48 hrs after start of treatment
Secondary Outcome Measure Information:
Title
Reduction of severity of diarrhoea
Description
Reduction of severity of diarrhoea will be evaluated as though : Number of watery (type 3A ISS ) and soft ( 3B ISS) stools daily on each of the day of the therapy and up to 5 days. Proportion of children with watery (3A ISS) and soft ( 3B ISS) stools on each of the day 1-5 (Day 0 = day of enrolment and start of treatment, day 1 = first complete day of treatment) Νumber of vomiting episodes: per child on each of the treatment days 1-5. Volume of ORS intake during the first 24h of treatment. Need of hospitalization Absence of workdays for the parents. Child's absence from day care / nursery. Medication needed for treatment of diarrhoea.
Time Frame
120 hrs from the start on treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
36 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 6 - 36 months old children 3 or more watery or soft stools per day for the past 24-48 hours Clinically judged as having mild to moderate dehydration (Bailey scale scores 1 to 4) Available throughout the study period Re-examination on the 7th day from the enrolment The signed informed consent by one/both parents or legal guardian Parents or legal guardian should have the mental ability to understand and willingness to fulfil all the details of the protocol Exclusion Criteria: Diarrhoea lasting more than 48 h Clinical signs of severe dehydration (Bailey scale scores = or > 5) Malnutrition as judged by a body weight/height ratio below the 5th percentile Clinical signs of a coexisting severe acute systemic illness (meningitis, sepsis, pneumonia) Immunodeficiency Severe chronic disease including cystic fibrosis Food allergy diagnosed by physician or other chronic gastrointestinal diseases Use of pre-/probiotics in the previous 2 weeks, for example infant formula containing probiotics and/or prebiotics. Use of antibiotics or any anti-diarrhoeal medication in the previous 4 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra Papadopoulou, Dr
Organizational Affiliation
Athens Children's Hospital "AGIA SOPHIA"
Official's Role
Principal Investigator
Facility Information:
Facility Name
Athens Children's Hospital "AGIA SOPHIA"
City
Athens
State/Province
Attica
ZIP/Postal Code
11527
Country
Greece

12. IPD Sharing Statement

Learn more about this trial

Efficacy of an Oral Rehydration Solution Containing the Probiotic Lactobacillus Reuteri Protectis and Zinc in Infants With Acute Gastroenteritis

We'll reach out to this number within 24 hrs